LCT is US-bound
Tuesday, 29 July, 2008
Auckland's diabetes transplant company Living Cell Technologies [ASX: LCT] has appointed a new CEO based in the US.
The current chief, Dr Paul Tan, will remain CEO of LCT New Zealand and will also take up the role of chief operating officer for the company.
The new CEO is Dr Robert Caspari, an LCT director and former head of Aurogen. He is based in Boulder, Colorado, and will lead development of the company from there. LCT recently listed American depository receipts on the International OTCQX, a market aimed at small to medium publicly listed companies.
Caspari has held positions with several pharma companies including Novo Nordisk, Baxter, Boehringer Mannheim, and Schering-Plough.
LCT plans a clinical trial at the Barbara Davis Centre for Diabetes in Denver next year.
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
